Prot# CHCD122A2103: A Phase IA/II, Multi-Center, Open-Label Study of HCD122 Administered Intravenously Once Weekly for Four Weeks in Adult Patients with Advanced Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

Project: Research project

Project Details

StatusFinished
Effective start/end date5/5/09 → 3/29/11

Funding

  • Novartis Pharmaceuticals Corporation (Prot# CHCD122A2103)